Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
Healthcare
$2.95 -0.94%
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
52W Low $3.60High $10.99
Volume 1.76M
Average 0.86M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$98.56M
FY 2025 · Annual
Investing Cash Flow
-$90.25M
FY 2025 · Annual
Financing Cash Flow
$216.79M
FY 2025 · Annual
+144.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 379K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 386K | 1.78M | 3.04M | 12.47M | 12.13M |
| Change in Working Capital | 6.04M | 1.79M | 1.48M | 2.73M | (9.52M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.02M | (426K) | (180K) | 2.38M | (1.56M) |
| Other Working Capital | 3.03M | 2.22M | 1.66M | 351K | (7.95M) |
| Other Non-Cash Items | 0 | 0 | 530K | (23K) | (1.6M) |
| Operating Cash Flow | (44.18M) | (54.56M) | (59.5M) | (81.15M) | (98.56M) |
| Capital Expenditures | (188K) | (901K) | (165K) | (481K) | (397K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (93.6M) | (195.4M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 105.53M |
| Other Investing Activities | 0 | (229K) | (50K) | 0 | 17K |
| Investing Cash Flow | (188K) | (901K) | (165K) | (94.08M) | (90.25M) |
| Debt Repayment | 0 | (163K) | 3.58M | (410K) | (533K) |
| Common Stock Issued | 170K | 332K | 100.25M | 88.71M | 217.33M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (203K) | 332K | (35K) | 491K | 0 |
| Financing Cash Flow | 150.86M | 189K | 103.79M | 88.78M | 216.8M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.49M | (55.27M) | 44.13M | (86.45M) | 27.98M |
| Free Cash Flow | (44.37M) | (55.46M) | (59.66M) | (81.63M) | (98.96M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$100.0M
+ D&A$379.0K
+ Stock-Based Comp$12.1M
+ Deferred Tax$0
- Working Capital-$9.5M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$98.6M
- Capex-$397.0K
= Free Cash Flow-$99.0M
Analysis
FY2025 free cash flow is -$99.0M. FCF conversion is 99.0% of net income. Operating cash flow was -$98.6M, with capex of -$397.0K. The largest bridge item is Stock-Based Comp at $12.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| EFFECT | EFFECT filing | Nov 4, 2026 | |
| S-3 | S-3 filing | Oct 29, 2026 | |
| SC 13G | SC 13G filing | Oct 13, 2026 |
Does LXEO generate free cash flow?
Lexeo Therapeutics, Inc. Common Stock (LXEO) generated -$98.96M of free cash flow in fiscal 2025.
How much operating cash flow does LXEO produce?
Operating cash flow was -$98.56M, before capital expenditures of $397,000.00.
Continue the stock analysis
Jump to another research area for this company.